Holen Sie sich die Stockscreener-App
0.0126
2.44%
0.0003
Handel nachbörslich:
.01
-0.0026
-20.63%
Vincerx Pharma Inc Aktie (VINC) Neueste Nachrichten
VINC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Head to Head Comparison: Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO) - Defense World
Critical Review: Vincerx Pharma (NASDAQ:VINC) & Trevena (NASDAQ:TRVN) - Defense World
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Analyzing Vincerx Pharma (NASDAQ:VINC) & Petros Pharmaceuticals (NASDAQ:PTPI) - Defense World
Head to Head Analysis: Vectura Group (OTCMKTS:VEGPF) and Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) Stock forecasts - Yahoo
Analyzing Neoleukin Therapeutics (NASDAQ:NLTX) & Vincerx Pharma (NASDAQ:VINC) - Defense World
Vincerx Pharma, Inc. (VINC) stock price, news, quote and history - Yahoo
Vincerx Pharma, Inc.Common Stock (NQ: VINC - FinancialContent
Vincerx Pharma ends sales agreement, approves reverse stock split - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders - ACCESS Newswire
Vincerx Pharma, Inc. Announces Additional Adjournment of - GlobeNewswire
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - The Manila Times
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR - GlobeNewswire
Vincerx Pharma, Inc. Announces Adjournment of Special MeetingWill Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal - Yahoo Finance
At a crossroads, biotechs are passing on reverse mergers in 2025 - Endpoints News
Global Digital Holdings Inc. cancelled the acquisition of Vincerx Pharma, Inc. in a reverse merger transaction. - marketscreener.com
VINC: Vincerx Pharma to dissolve, with minimal or no distributions expected for stockholders - TradingView
VINC Stock Price, News & Analysis - Stock Titan
VINC Stock Price and Chart — OTC:VINC - TradingView
VINC stock touches 52-week low at $0.17 amid sharp annual decline - Investing.com
Vincerx Pharma Announces Suspension and Intent to Delist Common Stock from Nasdaq - Nasdaq
vincerx pharma cancels merger, initiates wind-down activities - Investing.com
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down - Fierce Biotech
Vincerx Pharma ends merger talks, begins asset wind-down - Investing.com
VINC Stock Plummets to 52-Week Low of $0.48 Amid Steep Decline - Investing.com
Vincerx Pharma Inc. (VINC) reports earnings - qz.com
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis - Fierce Biotech
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - insights.citeline.com
Cash-strapped Vincerx left mulling future after Oqory reverse merger falls apart - Fierce Biotech
Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - Yahoo Finance
Vincerx Pharma, Inc. and Oqory, Inc. Highlight Promising Data for Oqory’s TROP2 Antibody Drug Conjugate, OQY-3258 - Yahoo Finance
Vincerx Pharma, Inc. Announces 1-for-20 Reverse Stock Split Effective January 27, 2025 - Nasdaq
Palo Alto's Vincerx Pharma plans reverse stock split amid merger plans - The Business Journals
Vincerx Pharma, Inc. Announces Reverse Stock Split - GlobeNewswire
Vincerx Pharma enters at-the-market equity offering deal - Investing.com
Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc.VINC | FinancialContent - FinancialContent
Vincerx acquisition leads to C-suite shake-up—Chutes & Ladders - Fierce Biotech
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Vincerx Pharma Stock Rises On Proposed Merger With Oqory: Retail Remains Bullish - Asianet Newsable
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. - Yahoo Finance
Vincerx Pharma Stock Gets Retail Followers Buzzing With Big Layoff Plans To Sustain Cancer Drug Trials - Stocktwits
Vincerx Pharma Inc (VINC) Quarterly 10-Q Report - qz.com
What Makes Vincerx Pharma (VINC) a New Buy Stock - Yahoo Finance
VINC Stock Touches 52-Week Low at $0.51 Amid Market Challenges - Investing.com
Vincerx reports two complete responses in VIP943 study By Investing.com - Investing.com UK
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants - Investing News Network
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - Investing News Network
Vincerx Pharma announces proposed underwritten public offering of common stock and warrant - Seeking Alpha
Vincerx Blames Stock Plunge On Overheated ADC Expectations - insights.citeline.com
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace
Vincerx Pharma Presents Positive Preliminary Phase 1 Data - GlobeNewswire
Pre-market Movers: NKGN, CELZ, AFMD, EVA, VINC.... - RTTNews
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Stock Titan
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023 - Yahoo Finance
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943 - Stock Titan
Vincerx Pharma Announces FDA Clearance of IND for VIP943 - GlobeNewswire
Andrew I Mcdonald Net Worth (2025) - GuruFocus
Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD - Bioprocess Online
John C. Byrd Net Worth (2026) - GuruFocus
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Yahoo Finance
Vincerx Pharma, Inc. (VINC) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update - GlobeNewswire
David Efraim Rosen Net Worth (2025) - GuruFocus
Vincerx Pharma Provides American Society of Hematology - GlobeNewswire
What is the current Price Target and Forecast for Vincerx Pharma (VINC) - Zacks Investment Research
Vincerx Pharma Provides Key Strategic Update - GlobeNewswire
Thursday 7/1 Insider Buying Report: VINC, FULC - Nasdaq
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, - GlobeNewswire
0.28%
17.88%
Kapitalisierung:
|
Volumen (24h):